Background and Objective: Detection of BRAF V600E gene mutation in Malignant Melanoma (MM) is essential in offering anti BRAF targeted therapy for MM patients. Expression of BRAF V600E mutant protein detected using immunohistochemistry (IHC) is afforadble, rapid, and reliable. This study aimed to measure the sensitivity and specificity of IHC compared to BRAFV 600E immunoexpression by molecular detection. Method: This study used paraffin block of acral MM patients to analyze BRAF V600E mutation status using anti BRAF V600E IHC compared to Real Time Polymerase Chain Reaction (RT PCR) which is a gold standard. Result: In total, ninety six samples were tested using IHC and RT-PCR. RT-PCR showed that 15 (15.6%) samples were positive for BRAF...
Bc.Veronika Hrabcová BRAF mutations in metastatic malignant melanoma. Diploma thesis Charles Univers...
Screening for theranostic biomarkers is mandatory for the therapeutic management of cutaneous melano...
Background: Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BR...
This study investigated the sensitivity and specificity of immunohistochemical (IHC) analysis using ...
In metastatic melanoma, the detection of somatic mutations in the BRAF gene is crucial regarding pat...
In metastatic melanoma, the detection of somatic mutations in the BRAF gene is crucial regarding pat...
Background and aims: BRAF or NRAS mutations occur in approximately 60% of cutaneous melanomas, and t...
BACKGROUND:Metastatic melanoma is a severe disease with one of the highest mortality rate in skin di...
A novel mutation-specific monoclonal antibody VE1 was generated to detect BRAF V600E mutation with i...
Metastatic melanoma is a fatal disease with poor prognosis. Ever since targeted therapy against onco...
<p>(A) PCR results indicating the presence or absence of the BRAF<sup>V600E</sup> mutation. Cells ex...
Abstract Personalized cancer care requires reliable bio-markers. While the BRAF V600E mutation is im...
Melanoma patients with BRAF mutations respond to treatment with vemurafenib, thus creating a need fo...
WOS: 000369490000004PubMed ID: 26630683Background:The BRAF-V600 mutation is the most common mutation...
Although the detection of BRAF p.V600E mutation by immunohistochemistry was clearly described in mel...
Bc.Veronika Hrabcová BRAF mutations in metastatic malignant melanoma. Diploma thesis Charles Univers...
Screening for theranostic biomarkers is mandatory for the therapeutic management of cutaneous melano...
Background: Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BR...
This study investigated the sensitivity and specificity of immunohistochemical (IHC) analysis using ...
In metastatic melanoma, the detection of somatic mutations in the BRAF gene is crucial regarding pat...
In metastatic melanoma, the detection of somatic mutations in the BRAF gene is crucial regarding pat...
Background and aims: BRAF or NRAS mutations occur in approximately 60% of cutaneous melanomas, and t...
BACKGROUND:Metastatic melanoma is a severe disease with one of the highest mortality rate in skin di...
A novel mutation-specific monoclonal antibody VE1 was generated to detect BRAF V600E mutation with i...
Metastatic melanoma is a fatal disease with poor prognosis. Ever since targeted therapy against onco...
<p>(A) PCR results indicating the presence or absence of the BRAF<sup>V600E</sup> mutation. Cells ex...
Abstract Personalized cancer care requires reliable bio-markers. While the BRAF V600E mutation is im...
Melanoma patients with BRAF mutations respond to treatment with vemurafenib, thus creating a need fo...
WOS: 000369490000004PubMed ID: 26630683Background:The BRAF-V600 mutation is the most common mutation...
Although the detection of BRAF p.V600E mutation by immunohistochemistry was clearly described in mel...
Bc.Veronika Hrabcová BRAF mutations in metastatic malignant melanoma. Diploma thesis Charles Univers...
Screening for theranostic biomarkers is mandatory for the therapeutic management of cutaneous melano...
Background: Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BR...